Financial Performance - The company's operating revenue for the first half of 2023 was CNY 867,389,372.66, a decrease of 1.36% compared to CNY 879,376,842.75 in the same period last year[21]. - The net profit attributable to shareholders of the listed company increased by 6.85% to CNY 84,467,995.97, up from CNY 79,054,003.85 in the previous year[21]. - The net cash flow from operating activities decreased significantly by 87.21% to CNY 5,888,482.78, compared to CNY 46,030,589.60 in the same period last year, primarily due to reduced project payments from Tianyuan Water Supply Company[21]. - Basic earnings per share for the first half of 2023 were CNY 0.10, an increase of 11.11% compared to CNY 0.09 in the same period last year[23]. - The diluted earnings per share also rose to CNY 0.10, marking an 11.11% increase from the previous year[23]. - The company reported a 17.81% increase in net profit after deducting non-recurring gains and losses, reaching CNY 75,573,760.67 compared to CNY 64,150,355.89 last year[21]. - The company achieved a total revenue of 867.39 million yuan, a decrease of 1.36% compared to the same period last year[61]. - The company reported a net profit attributable to shareholders of 84.47 million yuan, an increase of 6.85% year-on-year[61]. Assets and Liabilities - The total assets at the end of the reporting period were CNY 6,487,051,719.02, down 3.13% from CNY 6,696,905,336.93 at the end of the previous year[22]. - The net assets attributable to shareholders of the listed company decreased slightly by 0.10% to CNY 3,011,582,266.45 from CNY 3,014,592,194.05 at the end of the previous year[22]. - Total liabilities decreased to CNY 3,096,804,165.96 from CNY 3,294,827,608.70, a reduction of approximately 6%[188]. - The company’s total liabilities decreased by 43.68% to 1,222,017.74 from 2,169,663.03, mainly due to a reduction in output tax payable[67]. - The company’s total equity decreased to CNY 3,390,247,553.06 from CNY 3,402,077,728.23, reflecting a decline of about 0.35%[188]. Revenue Segments - The company's revenue from environmental engineering, solid waste disposal, and thermal power generation reached 421 million RMB, accounting for 48.82% of total revenue in the first half of 2023[30]. - The revenue from environmental engineering was 199 million RMB with a gross margin of 17.69%, while solid waste disposal generated 139 million RMB with a gross margin of 13.02%[30]. - The thermal power generation segment reported a revenue of 83 million RMB but had a negative gross margin of -26.28%[31]. - The biological pesticide segment reported revenue of 165 million yuan, representing a year-on-year increase of 4.58%[61]. - The water operation segment's revenue reached 264 million yuan, an increase of 10.54% compared to the previous year[61]. Market and Industry Insights - The ecological environmental industry is expected to exceed 3 trillion RMB in revenue by 2025, indicating significant market growth potential[28]. - The water industry is entering a mature phase, with opportunities arising from national policies promoting infrastructure development and wastewater treatment[34]. - The solid waste disposal and resource recovery sectors are identified as new growth points within the ecological environmental industry[29]. - The ecological environmental industry is facing challenges such as insufficient industry chain extension and intense product homogeneity competition[30]. Environmental Compliance and Management - The company has established a complete operational system to control pollution and ensure compliance with environmental standards[80]. - The company has reported no instances of exceeding pollution discharge standards in its wastewater and air emissions[92][93]. - The company is actively monitoring soil and groundwater for pollution risks and has submitted relevant reports[94]. - The company has implemented measures to ensure that its pollution discharge points comply with environmental management requirements[92][93]. - The company has established a comprehensive environmental risk monitoring system across its subsidiaries to ensure compliance with local environmental regulations[95]. Research and Development - The company has over 50 active products in the plant growth regulator sector, with a sales network covering most provinces in China and several overseas markets[33]. - The company has developed five new products, including a 5% gibberellin A4+A7 soluble solution, and is leading the industry standard formulation for gibberellin A4+A7 raw materials[51]. - Research and development efforts led to the completion of 5 new formulation products, with 2 selected as "green high-quality pesticide products" by the China Agricultural Industry Association[61]. Shareholder and Corporate Governance - The total number of ordinary shareholders as of the end of the reporting period is 25,000[173]. - The largest shareholder, Haining Water Investment Group Co., Ltd., holds 389,756,986 shares, representing 44.98% of the total shares[177]. - Haining Water Group and Yunnan Water committed to a net profit of no less than RMB 115 million, RMB 127 million, and RMB 142 million for the years 2021, 2022, and 2023 respectively, after deducting non-recurring gains and losses[143]. - The commitments made by Haining Water Group and Yunnan Water are legally binding and aim to protect the rights of Qianjiang Biochemical and its shareholders[154]. Cash Flow and Financing Activities - Cash inflows from operating activities decreased to CNY 878,362,558.66 in the first half of 2023 from CNY 1,043,034,344.00 in the same period of 2022, a decline of approximately 15.8%[199]. - The total cash inflow from investment activities was significantly lower than the previous year's total of 237,555,039.06[200]. - Cash inflow from financing activities amounted to 124,804,939.01, with cash outflow totaling 271,270,810.08, leading to a net cash flow of -146,465,871.07[200].

股票简称：钱江生化 证券代码：600796 编号：临 2023-027 浙江钱江生物化学股份有限公司（以下简称"公司"）十届五次监事会会议 于2023年8月24日，以现场表决方式在公司会议室召开。会议通知于2023年8月14 日以书面及电子邮件方式发出。会议应到监事三名，实到监事三名，监事会主席 余强主持了会议，本次会议的召开符合《公司法》及《公司章程》的规定。 二、监事会会议审议情况 （一）审议通过了《公司 2023 年半年度报告及其摘要》； 监事会全体人员对上述议案进行了认真审议，并发表以下意见： 报告期内，公司的财务核算体制健全，会计事项的处理、财务报表的编制及 公司执行的会计制度符合有关法律法规的要求。公司 2023 年半年度报告及摘要 编制和审议程序符合法律、法规、公司章程和公司内部管理制度的各项规定；2023 年半年度报告及摘要的内容和格式符合中国证监会和上海证券交易所的各项规 定，所包含的信息能从各个方面真实地反映出公司当期的经营管理和财务状况等 事项，财务报告中的数据真实。 浙江钱江生物化学股份有限公司 十届五次监事会决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 ...

证券代码：600796 股票简称：钱江生化 编号：临 2023—028 浙江钱江生物化学股份有限公司 2023 年半年度募集 资金存放与实际使用情况的专项报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 根据《上市公司监管指引第2号——上市公司募集资金管理和使用的监管要 求》《上海证券交易所上市公司自律监管指引第1号——规范运作》等有关规定， 浙江钱江生物化学股份有限公司（以下简称"公司"或"本公司"）董事会编制 了截至2023年6月30日止的《2023年半年度募集资金存放与实际使用情况的报 告》，内容如下： 一、募集资金基本情况 (一) 实际募集资金金额和资金到账时间 根据中国证券监督管理委员会《关于核准浙江钱江生物化学股份有限公司向 海宁市水务投资集团有限公司等发行股份购买资产并募集配套资金的批复》（证 监许可〔2021〕3803 号），本公司由主承销商中信证券股份有限公司采用非公 开发行方式，向特定对象非公开发行人民币普通股（A 股）股票 90,420,643 万 股，发行价为每股人民币 3.94 元，共计募集 ...

证券代码：600796 证券简称：钱江生化 公告编号：临 2023-030 浙江钱江生物化学股份有限公司 关于召开 2023 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2023 年 08 月 25 日(星期五) 至 08 月 30 日(星期 三)16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或 通过公司邮箱 qjsh600796@126.com 进行提问。公司将在说明会上对投 资者普遍关注的问题进行回答。 浙江钱江生物化学股份有限公司（以下简称"公司"）于 2023 年 8 月 25 日发布公司 2023 年半年度报告，为便于广大投资者更全面深 入地了解公司 2023 年半年度经营成果、财务状况，公司计划于 2023 年 08 月 31 日 上午 09:00-10:00 举行 2023 年半年度业绩说明会， 就投资者关心的问题进行交流。 （一） 会议召开时间 ...

独立黄事独立意见 根据《上市公司独立董事规则》《关联交易实施指引》《上海证券交易所 股票上市规则》和《公司章程》的有关规定,我们作为浙江钱江生物化学股份有 限公司(以下简称"公司")的独立董事,对公司十届五次董事会审议的相关议 案发表独立意见如下: 1、《2023 年半年度募集资金存放与实际使用情况的专项报告》 我们认为:公司《2023年半年度募集资金存放与实际使用情况的专项报告》 已按照《上市公司监管指引第 2 号 -- 上市公司募集资金管理和使用的监管要 求》《上海证券交易所上市公司自律监管指引第1 号 -- 规范运作》等的相关规 定真实、准确、完整、及时的披露了公司募集资金的存放及实际使用情况,公司 2023 年半年度不存在募集资金管理违规的情况。我们同意公司 2023年半年度募 集资金存放与实际使用情况的专项报告。 2、《关于支付现金购买资产暨关联交易的议案》 我们认为: 本次关联交易有效兑现了控股股东海宁市水务投资集团有限公司 作出的避免同业竞争承诺,有助于减少控股股东和公司之间的同业竞争:关联交 易价格以具有从事证券、期货业务资格的资产评估公司出具的评估报告为定价依 据,以评估值为依据确定,价格公 ...

重要内容提示： 一、董事会会议召开情况 浙江钱江生物化学股份有限公司（以下简称"公司"）十届五次董事会会议 于 2023 年 8 月 24 日在公司会议室以现场和通讯相结合方式召开。会议通知于 2023 年 8 月 14 日以书面及电子邮件方式发出。会议应到董事九名，实到董事九 名，董事周志密先生、独立董事裘益政先生、韦彦斐先生以通讯方式表决。三名 监事及高管人员列席了会议。会议由公司董事长阮国强先生主持，本次会议的召 开符合《公司法》及《公司章程》的规定。 证券代码：600796 股票简称：钱江生化 编号：临 2023—026 浙江钱江生物化学股份有限公司 十届五次董事会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 二、董事会会议审议情况 （一）审议通过了《公司 2023 年半年度报告及其摘要》 表决结果：9 票同意、0 票反对、0 票弃权。 《公司 2023 年半年度报告》《公司 2023 年半年度报告摘要》详见上海证券 交易所网站（www.sse.com.cn），《公司 2023 年半年度报告摘要》同日 ...

●本次交易前后，公司的实际控制人均为海宁市人民政府国有资产监督管理 办公室，控股股东均为水务集团，本次交易不会导致上市公司控制权变更，根据 《重组管理办法》的相关规定，本次交易不构成重大资产重组，本次交易不构成 借壳上市。 ●本次交易事项已经公司十届五次董事会审议通过，无需提交公司股东大会 审议。 证券代码：600796 股票简称：钱江生化 编号：临 2023—029 浙江钱江生物化学股份有限公司 关于支付现金购买资产暨关联交易的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： ●投资标的名称：海宁钱塘水务有限公司（以下简称"钱塘水务"）部分资 产 ●交易简要内容：公司全资孙公司海宁紫光水务有限责任公司（以下简称"紫 光水务"）以 1,559.37 万元购买钱塘水务部分资产。 ●本次交易对象系公司控股股东海宁市水务投资集团有限公司（以下简称 "水务集团"）之全资子公司钱塘水务，本次交易构成关联交易，关联董事在董 事会审议本次交易相关事项时已回避表决。 ●过去12个月与同一关联人开展的关联交易情况：20 ...

浙江钱江生物化学股份有限公司 独立黄事事前认可意见 浙江钱江生物化学股份有限公司董事会: 根据中国证监会和《公司法》《证券法》《上市公司治理准则》以及《浙江 钱江生物化学股份有限公司章程》的有关规定,作为浙江钱江生物化学股份有限 公司(以下简称"公司")的独立董事,对十届五次董事会审议的《关于支付现 金购买资产暨关联交易的议案》进行了事前审议,发表如下事前认可意见: 我们对相关资料进行审阅,认为本次交易符合公司经营发展需要,有效兑现 了控股股东海宁市水务投资集团有限公司作出的避免同业竞争承诺,有助于减少 控股股东和公司之间的同业竞争,不影响公司独立性,不存在损害公司及股东特 别是中小股东利益的情形。同意将上述议案提交公司十届五次董事会审议。 独立董事(签字): 我们对相关资料进行审阅,认为本次交易符合公司经营发展需要,有效兑现 了控股股东海宁市水务投资集团有限公司作出的避免同业竞争承诺,有助于减少 控股股东和公司之间的同业竞争，不影响公司独立性,不存在损害公司及股东特 别是中小股东利益的情形。同意将上述议案提交公司十届五次董事会审议。 独立董事(签字): 王利伏- 手放线- 2023年8月24日 日描全能王 ...

证券代码：600796 证券简称：钱江生化 公告编号：临 2023-022 浙江钱江生物化学股份有限公司 关于召开 2022 年度暨 2023 年第一季度业绩说明会的 公告 会议召开地点：上海证券交易所上证路演中心（网址： http://roadshow.sseinfo.com/） 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 会议召开时间：2023 年 05 月 30 日(星期二) 上午 10:00-11:00 一、 说明会类型 本次投资者说明会以网络互动形式召开，公司将针对 2022 年度 的经营成果及财务指标的具体情况与投资者进行互动交流和沟通，在 信息披露允许的范围内就投资者普遍关注的问题进行回答。 二、 说明会召开的时间、地点 （一） 会议召开时间：2023 年 05 月 30 日 上午 10:00-11:00 （二） 会议召开地点：上证路演中心 （三） 会议召开方式：上证路演中心网络互动 三、 参加人员 董事长：阮国强 会议召开方式：上证路演中心网络互动 投资者可于 2023 年 05 月 ...

Financial Performance - The net profit attributable to shareholders for the year 2022 was 206 million yuan, representing a year-on-year increase of 39.28%, primarily due to increased investment income [23]. - The company achieved operating revenue of CNY 2.01 billion in 2022, a decrease of 1.09% compared to the previous year [24]. - Net profit attributable to shareholders increased by 39.28% to CNY 206.05 million in 2022, up from CNY 147.94 million in 2021 [24]. - The company's cash flow from operating activities was CNY 401.94 million, reflecting a 9.03% increase from CNY 368.65 million in 2021 [24]. - The total revenue for the year was approximately 2,004,405,817.88, a decrease of 21.97% compared to the previous year [80]. - The revenue from domestic sales was 1,919,614,964.03, reflecting a decrease of 1.67% year-over-year [80]. - The revenue from international sales increased by 25.35% to 84,790,853.85, with a gross margin of 44.57% [80]. - The gross margin for the overall business was 21.91%, a slight decrease of 0.76% year-over-year [80]. - The company reported a significant increase in the disposal of medical waste, with a sales volume of 12,038.91 tons, up by 67.87% [81]. - The total revenue for the year reached 1,565,271,459.56 million, a slight increase of 0.19% compared to the previous year [91]. Dividend Distribution - The company plans to distribute a cash dividend of 1.02 yuan per 10 shares, totaling 88.39 million yuan, based on a total share capital of 866,585,766 shares [5]. - The company distributed cash dividends totaling 86,658,576.60 yuan (including tax) to shareholders in 2022 [39]. - The cash dividend distributed accounted for 42.90% of the net profit attributable to ordinary shareholders in the consolidated financial statements [183]. - The company has a cash dividend policy that mandates a minimum distribution of 30% of the average distributable profit over the last three years [180]. - The company has not proposed a cash profit distribution plan despite having positive distributable profits for shareholders during the reporting period [182]. Operational Efficiency and Cost Management - The company saved 799.2352 million yuan through optimized procurement processes, with a total bidding budget of 146.1833 million yuan and an actual winning bid of 138.190948 million yuan [35]. - The company reported a decrease in financing cash flow, with a net outflow of 343.83 million RMB, compared to a net inflow of 570.27 million RMB in the previous year [77]. - The total cost of raw materials decreased by 21.57% to 128,792,348.43, compared to 164,219,951.72 in the previous year [83]. - Total manufacturing costs decreased by 23.35% to $234,453,816.03 from $305,865,496.46 [84]. - The company plans to implement strict cost control measures to improve financial management and reduce operational costs [125]. Environmental and Social Responsibility - The company actively participated in social welfare activities, contributing a total of 771,500 yuan to local schools and poverty alleviation efforts [39]. - The company invested 8.762 million yuan in environmental protection during the reporting period [189]. - The company is committed to enhancing safety management and ensuring compliance with environmental standards across its operations [127]. - The company has established a standardized hazardous waste storage facility, ensuring compliance with environmental management requirements [192]. - The company is classified as a key pollutant discharge unit in terms of air and water environment, adhering to relevant environmental standards [190]. Corporate Governance and Management - The company has confirmed that all board members attended the board meeting, ensuring the authenticity and completeness of the annual report [8]. - The company received a standard unqualified audit report from Tianjian Accounting Firm [4]. - The company has established an independent financial management department with a separate accounting system and independent bank accounts, ensuring no interference from the controlling shareholder in financial decisions [143]. - The company has held multiple shareholder meetings, approving various proposals related to financial management and governance, ensuring compliance with regulations [145]. - The company has undergone a board and management restructuring effective from May 30, 2022 [149]. Research and Development - Research and development expenses amounted to 31.45 million RMB, a slight decrease of 1.81% from 32.03 million RMB in the previous year [76]. - The company is developing a third-generation pyrolysis device aimed at improving operational stability and efficiency, which is expected to enhance market competitiveness [97]. - The company has established a research center for microbial fermentation and biological active products, enhancing its competitive edge in the market [72]. - The company completed the development and registration of several new pesticide formulations, including high-concentration products [100]. - The company is actively expanding its product line with microbial fertilizers, enhancing its market presence and profitability [101]. Market and Industry Trends - The water industry in China is projected to reach a revenue scale of 562.5 billion yuan by 2026, with a compound annual growth rate of 12.92% from 2010 to 2020 [47]. - The smart water industry market size was approximately 12.48 billion yuan in 2020, with an expected growth to 21.4 billion yuan by 2023, reflecting a compound annual growth rate of about 20% [48]. - The biopesticide industry is expected to see a stable supply of pesticides to ensure national food security, with a focus on green and efficient development in line with the "14th Five-Year Plan" for agriculture [119]. - The pesticide industry is facing pressure from high raw material prices, with some products experiencing significant price drops, impacting profitability for producers [120]. - The company aims to leverage opportunities from carbon neutrality and domestic international dual circulation, focusing on digital empowerment and business innovation as key drivers [122]. Risk Management - The company has established a risk prevention and control mechanism, including pre-risk prevention, in-process monitoring, and post-evaluation optimization [186]. - The company is managing risks related to accounts receivable and cash flow, particularly due to the reliance on BOT and PPP models which can lead to slower cash inflows [136]. - The company is monitoring raw material price trends, especially natural gas, which has seen significant price increases due to geopolitical factors [137]. - The company has detailed risk factors in the report, advising investors to review the section on potential risks [7]. - The company has no significant internal control deficiencies during the reporting period [186].